open access

Vol 10, No 4 (2005)
Original Paper
Published online: 2005-01-01
Submitted: 2004-11-23
Get Citation

An analysis of outcomes, after re-irradiation by HDR (high-dose-rate) brachytherapy, among patients with locally recurrent nasopharyngeal carcinoma (NPC)

Joanna Terlikiewicz, Roman Makarewicz, Andrzej Lebioda, Renata Kabacińska, Marta Biedka
DOI: 10.1016/S1507-1367(05)71092-0
·
Rep Pract Oncol Radiother 2005;10(4):193-201.

open access

Vol 10, No 4 (2005)
Original Paper
Published online: 2005-01-01
Submitted: 2004-11-23

Abstract

Background

Despite aggressive treatment with radiotherapy, which is often combined with chemotherapy, local persistence occurs in 18–40% of patients with nasopharyngeal carcinoma. Brachytherapy is one of the methods for the re-treatment of patients with locally recurrent nasopharyngeal carcinoma.

Aim

The aim of this paper was to evaluate the effectiveness of HDR (high-dose-rate) treatment of patients with locally recurrent nasopharyngeal carcinoma.

Materials/Methods

The study took the form of a retrospective analysis and included a group of 28 patients treated in the Brachytherapy Department of the Oncology Centre in Bydgoszcz during the years 1995–2000. Brachytherapy was carried out using a Rotterdam applicator and the MicroSelectron HDR apparatus produced by Nucletron. Irradiation was based on doses of 36 Gy, i.e. 6 Gy applied once a week, and 51 Gy i.e. 3 Gy applied twice a week. This paper presents recovery probability, overall survival and recurrence-free survival within the analysed group of patients.

Results

The results obtained prove intracavitary HDR (high-dose-rate) brachytherapy to be a viable method for the treatment of patients with recurring nasopharyngeal carcinoma.

Conclusions

The higher the total dose applied by means of brachytherapy, the greater the chance of locally successful treatment, moreover, the time that elapses before recurrence is considered to be an important factor influencing recurrence-free survival time.

Abstract

Background

Despite aggressive treatment with radiotherapy, which is often combined with chemotherapy, local persistence occurs in 18–40% of patients with nasopharyngeal carcinoma. Brachytherapy is one of the methods for the re-treatment of patients with locally recurrent nasopharyngeal carcinoma.

Aim

The aim of this paper was to evaluate the effectiveness of HDR (high-dose-rate) treatment of patients with locally recurrent nasopharyngeal carcinoma.

Materials/Methods

The study took the form of a retrospective analysis and included a group of 28 patients treated in the Brachytherapy Department of the Oncology Centre in Bydgoszcz during the years 1995–2000. Brachytherapy was carried out using a Rotterdam applicator and the MicroSelectron HDR apparatus produced by Nucletron. Irradiation was based on doses of 36 Gy, i.e. 6 Gy applied once a week, and 51 Gy i.e. 3 Gy applied twice a week. This paper presents recovery probability, overall survival and recurrence-free survival within the analysed group of patients.

Results

The results obtained prove intracavitary HDR (high-dose-rate) brachytherapy to be a viable method for the treatment of patients with recurring nasopharyngeal carcinoma.

Conclusions

The higher the total dose applied by means of brachytherapy, the greater the chance of locally successful treatment, moreover, the time that elapses before recurrence is considered to be an important factor influencing recurrence-free survival time.

Get Citation

Keywords

nasopharyngeal carcinoma; locally recurrent carcinoma; HDR (high-dose-rate) brachytherapy; re-irradiation; radiotherapy

About this article
Title

An analysis of outcomes, after re-irradiation by HDR (high-dose-rate) brachytherapy, among patients with locally recurrent nasopharyngeal carcinoma (NPC)

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 10, No 4 (2005)

Pages

193-201

Published online

2005-01-01

DOI

10.1016/S1507-1367(05)71092-0

Bibliographic record

Rep Pract Oncol Radiother 2005;10(4):193-201.

Keywords

nasopharyngeal carcinoma
locally recurrent carcinoma
HDR (high-dose-rate) brachytherapy
re-irradiation
radiotherapy

Authors

Joanna Terlikiewicz
Roman Makarewicz
Andrzej Lebioda
Renata Kabacińska
Marta Biedka

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl